|Heat Biologics, Inc.|
801 Capitola Drive
United States - Map
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.
|Mr. Jeffrey Alan Wolf J.D.,
Founder, Chairman, Chief Exec. Officer, Pres and Treasurer
|Dr. Taylor H. Schreiber M.D., Ph.D.,
Chief Scientific Officer
|Dr. Melissa Price Ph.D.,
VP of Product Devel.
|Ms. Ann A. Rosar ,
VP of Fin., Corp. Sec. and Controller
|Dr. Justin Stebbing M.D., M.A. FRCP FRC Path Ph.D.,
Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|